Itraconazole

Edina Avdic, Pharm.D.
Pediatric Dosing Author: Lisa Hutchins, Pharm.D.
Itraconazole is a topic covered in the Johns Hopkins HIV Guide.

To view the entire topic, please log in or purchase a subscription.

Official website of the Johns Hopkins Antibiotic (ABX), HIV, Diabetes, and Psychiatry Guides, powered by Unbound Medicine. Johns Hopkins Guide App for iOS, iPhone, iPad, and Android included. Explore these free sample topics:

Johns Hopkins Guides

MonkeypoxMonkeypox

Coronavirus COVID-19 (SARS-CoV-2)Coronavirus COVID-19 (SARS-CoV-2)

Suicide Risk in the COVID-19 PandemicSuicide Risk in the COVID-19 Pandemic

Moderna COVID-19 VaccineModerna COVID-19 Vaccine

BNT162b2 COVID-19 Vaccine (BioNTech/Pfizer)BNT162b2 COVID-19 Vaccine (BioNTech/Pfizer)

Managing Stress and Coping with COVID-19Managing Stress and Coping with COVID-19

Johnson & Johnson COVID-19 VaccineJohnson & Johnson COVID-19 Vaccine

-- The first section of this topic is shown below --

INDICATIONS

FDA

  • Following fungal infections in immunocompromised and non-immunocompromised patients:
    • Aspergillosis: treatment-intolerant of or refractory to amphotericin B therapy
    • Pulmonary and extrapulmonary blastomycosis
    • Histoplasmosis, including chronic cavitary pulmonary disease and disseminated non-meningeal histoplasmosis
  • Onychomycosis in non-immunocompromised patients (oral capsule):
    • Onychomycosis of the toenail, with or without fingernail involvement, due to dermatophytes (tinea unguium)
    • Onychomycosis of the fingernail due to dermatophytes (tinea unguium).
  • Oropharyngeal and esophageal candidiasis (oral liquid)
  • Neutropenic fever in patients with suspected fungal infection (oral liquid).

NON-FDA APPROVED USES

  • Coccidioidomycosis
  • Cryptococcosis (fluconazole preferred)
  • Penicilliosis
  • Sporotrichosis
  • Candida vaginitis
  • Fluconazole-resistant esophageal candidiasis

-- To view the remaining sections of this topic, please log in or purchase a subscription --

INDICATIONS

FDA

  • Following fungal infections in immunocompromised and non-immunocompromised patients:
    • Aspergillosis: treatment-intolerant of or refractory to amphotericin B therapy
    • Pulmonary and extrapulmonary blastomycosis
    • Histoplasmosis, including chronic cavitary pulmonary disease and disseminated non-meningeal histoplasmosis
  • Onychomycosis in non-immunocompromised patients (oral capsule):
    • Onychomycosis of the toenail, with or without fingernail involvement, due to dermatophytes (tinea unguium)
    • Onychomycosis of the fingernail due to dermatophytes (tinea unguium).
  • Oropharyngeal and esophageal candidiasis (oral liquid)
  • Neutropenic fever in patients with suspected fungal infection (oral liquid).

NON-FDA APPROVED USES

  • Coccidioidomycosis
  • Cryptococcosis (fluconazole preferred)
  • Penicilliosis
  • Sporotrichosis
  • Candida vaginitis
  • Fluconazole-resistant esophageal candidiasis

There's more to see -- the rest of this topic is available only to subscribers.

© 2000–2022 Unbound Medicine, Inc. All rights reserved